NVDA Q3 Earnings Alert: Why our AI stock picker is still holding Nvidia stockRead More

US Senate Democrats seek compromise on drug imports

Published 12/11/2009, 07:47 PM
Updated 12/11/2009, 07:51 PM

* White House says not fighting drug importation plan

* PhRMA open to importation with safety certification

By Susan Heavey

WASHINGTON, Dec 11 (Reuters) - Democrats scrambled on Friday to resolve a stalemate over whether to permit imports of cheaper prescription drugs from Canada and elsewhere as part of a larger effort to overhaul the U.S. healthcare system.

Work on health reform legislation, President Barack Obama's top domestic priority, has stalled in the Senate over a bipartisan proposal to allow patients and pharmacies to import U.S. Food and Drug Administration-approved medications as long as they register with the federal agency.

Importing prescription drugs, also known as "reimportation," has been an issue for years as U.S. consumers look for cheaper alternatives for prescription medications that can cost hundreds or thousands of dollars a year, especially for those without health insurance.

Despite days of debate over the measure, Democrats remained divided over the issue in large part over safety concerns.

Some critics charged the real split was over the $80 billion, 10-year deal under which drug companies promised the White House and certain senators they would charge the government less for some medications and pay higher taxes.

The critics charge the industry would make up for any lost profits from the deal by raising prices elsewhere in the market. Financial analysts and others say the companies have already begun to charge more for many widely used medications.

Senator Sheldon Whitehouse said there was significant concern particularly among people not party to the deal that it may not have demanded enough from the pharmaceutical industry.

The industry could be more "helpful" in taking steps to win over skeptical lawmakers, he said in a conference call with Families USA, a consumer advocacy group that supports Democrats' push to overhaul the $2.5 trillion U.S. healthcare system.

Drugmakers are the largest health industry sector to back Obama's bid to expand access to healthcare.

'THERE ARE CONCERNS'

A White House official said the Obama administration was not fighting the drug importation proposal offered by Democratic Senator Byron Dorgan along with a number of Republicans, including Senator John McCain, who lost to Obama in last year's presidential election.

"That's just not true," said the official who asked not to be identified.

But suggesting the administration was less than enthusiastic about it, FDA Commissioner Dr. Margaret Hamburg sent a letter this week saying the agency supported drug importation but had safety concerns about Dorgan's plan.

The standoff has pushed back debate on the health bill until next week. Democratic Majority Leader Harry Reid has said he wants a final vote on the bill before Congress breaks for Christmas.

"There are concerns. It's something we're trying to work out," said Senator Charles Schumer. "I think it will be resolved in the next little while. I certainly don't think it will stand in the way of getting a bill."

Other Democrats have offered an alternative to allow drug imports as long as U.S. health officials deemed them safe.

Pharmaceutical Research and Manufacturers of America, or PhRMA, Senior Vice President Ken Johnson said importing drugs was dangerous but that the industry lobby group would not oppose importation measures that require such certification.

"There's no way for the FDA to guarantee the safety and efficacy of medicines brought to the United States outside of its control. There's no way to do it" he said. (Reporting by Susan Heavey; additional reporting by Donna Smith, John Whitesides and Patricia Zengerle; Editing by Arshad Mohammed and Peter Cooney)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.